Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 68.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 945,491 shares of the biopharmaceutical company’s stock after buying an additional 384,095 shares during the period. JPMorgan Chase & Co. owned approximately 0.40% of Esperion Therapeutics worth $2,506,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. DHJJ Financial Advisors Ltd. raised its holdings in Esperion Therapeutics by 209.2% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 6,380 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth $25,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at $29,000. R Squared Ltd acquired a new position in Esperion Therapeutics in the third quarter valued at $33,000. Finally, CWM LLC increased its stake in Esperion Therapeutics by 46.5% in the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 6,249 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics News Summary

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Athyrium agreed to a $50 million royalty financing in which funds managed by Athyrium will acquire Esperion’s royalty interest in Otsuka’s Japan sales of bempedoic acid (from Jan 1, 2026) plus related milestones (subject to a cap). This transaction provides immediate cash to fund strategy and de‑risk near‑term cash needs — a clear liquidity boost tied to the Corstasis deal. Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
• Positive Sentiment: Esperion closed its acquisition of Corstasis Therapeutics and integrated Enbumyst™ (bumetanide nasal spray), the first FDA‑approved nasal loop diuretic. Management says Enbumyst expands the cardiovascular franchise and should help drive portfolio diversification, commercial leverage and future revenue growth. That product addition is a strategic revenue driver beyond the company’s existing lipid franchise. Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
• Positive Sentiment: Zacks Research issued a forecast that includes a positive Q1 2028 EPS projection (estimated $0.14), signaling analyst expectations for the company to approach profitability in the 2027–2028 timeframe. That longer‑term upside helps offset short‑term headwinds in some models. Zacks Research Issues Positive Forecast for ESPR Earnings
• Negative Sentiment: Zacks Research also lowered multiple near‑term estimates: Q2 and Q3 2026 EPS were cut to ($0.02), FY2026 to ($0.04) from ($0.01), Q3/Q4 2027 and FY2027 targets were trimmed, and several quarterly forecasts were reduced. These downward revisions signal weaker near‑term profitability assumptions and could apply selling pressure until revenue from Enbumyst and the financing materially improves reported results. MarketBeat ESPR coverage (Zacks estimate changes)

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $2.61 on Monday. Esperion Therapeutics, Inc. has a 1 year low of $0.69 and a 1 year high of $4.18. The stock has a market capitalization of $670.27 million, a P/E ratio of -15.35, a PEG ratio of 2.12 and a beta of 1.17. The stock has a 50-day simple moving average of $3.06 and a 200-day simple moving average of $3.16.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analysts’ expectations of $165.12 million. Analysts predict that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ESPR. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Needham & Company LLC raised their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Citizens Jmp boosted their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a “market outperform” rating in a report on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.60.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.